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DObjective: Minimally invasive coronary artery bypass grafting is safe and widely applicable, and may be
associated with fewer transfusions and infections, and better recovery than standard coronary artery bypass
grafting. However, graft patency rates remain unknown. The Minimally Invasive Coronary Artery Bypass
Grafting Patency Study prospectively evaluated angiographic graft patency 6 months after minimally invasive
coronary artery bypass grafting.
Methods: In this dual-center study, 91 patients were prospectively enrolled to undergo minimally invasive
coronary artery bypass grafting via a 4- to 7-cm left thoracotomy approach. The left internal thoracic artery,
the ascending aorta for proximal anastomoses, and all coronary targets were directly accessed without
endoscopic or robotic assistance. The study primary outcome was graft patency at 6 months, using 64-slice
computed tomography angiography. Secondary outcomes included conversions to sternotomy and major
adverse cardiovascular events (Clinical Trial Registration Unique identifier: NCT01334866).
Results: Themean age of patients was 64 8 years, the mean ejection fraction was 51% 11%, and there were
10 female patients (11%) in the study. Surgeries were performed entirely off-pump in 68 patients (76%).
Complete revascularization was achieved in all patients, and the median number of grafts was 3. There was
no perioperative mortality, no conversion to sternotomy, and 2 reopenings for bleeding. Transfusion occurred
in 24 patients (26%). The median length of hospital stay was 4 days, and all patients were followed to 6 months,
with no mortality or major adverse cardiovascular events. Six-month computed tomography angiographic graft
patency was 92% for all grafts and 100% for left internal thoracic artery grafts.
Conclusions:Minimally invasive coronary artery bypass grafting is safe, feasible, and associated with excellent
outcomes and graft patency at 6 months post-surgery. (J Thorac Cardiovasc Surg 2014;147:203-9)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Caartery bypass grafting (CABG) is the safest and most
effective way to achieve myocardial revascularization in
patients with triple-vessel coronary artery disease
(CAD)1 and in diabetic patients with multivessel
CAD.2,3 In addition, a significant number of patients
have single-vessel CAD, most often involving the
proximal left anterior descending (LAD) artery, for
whom CABG is indicated because of the failure or
inability to perform percutaneous coronary intervention
or as a result of patient or cardiologist preference.4,5
Although CABG is safe and effective, its invasiveness
has not appreciably diminished over the last several
decades. The majority of CABG operations still involve a
median sternotomy and use cardiopulmonary bypass, aortic
crossclamping, and cardioplegia to induce cardiac arrest.
Safe, reproducible, and widely applicable ways to
perform CABG in a less-invasive manner must be explored
and investigated to safely build on the effectiveness of
CABG, while decreasing its physical and psychologic
trauma. To this end, we have introduced, and developed
with wide applicability, minimally invasive cardiac surgery
(MICS) CABG. Previous reports from our groups have
demonstrated (1) the safety and feasibility of this operation
in large numbers6,7; (2) the reproducibility of performing
proximal anastomoses onto the ascending aorta8,9; andrdiovascular Surgery c Volume 147, Number 1 203
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
CCS ¼ Canadian Cardiovascular Society
CTA ¼ computed tomography angiography
LAD ¼ left anterior descending
LITA ¼ left internal thoracic artery
MICS ¼ minimally invasive cardiac surgery
MIDCAB ¼ minimally invasive direct coronary
artery bypass
SVG ¼ saphenous vein graft
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D(3) the advantages of MICS CABG over sternotomy CABG
in terms of lesser transfusion of blood products, decreased
incidence of chest wound infection, and improved
postoperative physical recovery.10
Nevertheless, the graft patency results of MICS CABG
have so far been largely unknown. Although patency after
regular CABG can be high,11 possible concerns specific to
the MICS CABG operation include its increased technical
difficulty, the narrower exposure requiring more precise
control of the needle during anastomosis, a more restricted
selection of distal target sites, and a less intuitive
assessment of optimal graft length, all of which could
negatively affect graft patency rates.
Consequently, we designed this prospective cohort study
in which patients scheduled to receive MICS CABG by 1 of
2 experienced MICS CABG surgeons were enrolled to
undergo operation and followed for 6 months after
operation, and subsequently undergo computed tomogra-
phy angiography (CTA) assessment of the patency of their
grafts.MATERIALS AND METHODS
Study Objectives
The primary objective was to characterize technical success (graft
patency of each graft at 6 months) and procedural success in consented
patients scheduled to undergo a MICS CABG operation. The secondary
objective was the evaluation of major adverse events, defined as major
hemorrhage/bleeding requiring surgical intervention, aortic complications,
graft vessel revision or subsequent revascularization, transient ischemic
attack, cerebrovascular accident, myocardial infarction, or death, at both
30 days and 6 months after MICS CABG.
Study Design and Inclusion/Exclusion Criteria
The study was a prospective, consecutive patient enrollment,
dual-center study. Inclusion criteria included age greater than 18 years
and less than or equal to 80 years; nonemergency, first time, single or
multivessel CABG suitable for MICS CABG; and left ventricular ejection
fraction of more than 30%. Exclusion criteria were previous cardiac
surgery; a history of renal insufficiency with creatinine greater than 2
mg/dL; peripheral or systemic active infection; life expectancy of less
than 1 year because of other illness; uncontrolled acute myocardial
ischemia; New York Heart Association class IV heart failure symptoms;204 The Journal of Thoracic and Cardiovascular Surguncontrolled diabetes mellitus or hypertension; recent cerebrovascular
accident (within 90 days before operation); and female gender with
childbearing potential.
Operative Procedure
The operative and technical details of the MICS CABG operation have
been published.6,8,9 Briefly, harvest of the left internal thoracic artery
(LITA) over its entire usable length and cephalad to the level of the
subclavian vein, saphenous vein graft (SVG), or radial artery proximal
anastomoses handsewn onto the ascending aorta with a side-biting clamp
using 6-0 polypropylene, and distal coronary anastomoses handsewn using
7-0 polypropylene are performed under direct vision, without endoscopic
or robotic assistance, through a 4- to 7-cm incision in the left fourth or fifth
intercostal space, through which a Thoratrak (Medtronic, Inc, Minneapolis,
Minn) rib spreader and a Rultract Skyhook (Rultract, Cleveland, Ohio)
retractor are used. If exposure during proximal or distal anastomoses
is poor or the patient does not tolerate part of the procedure despite
hemodynamic support, including low-dose vasopressors, femoral arterial
and venous partial cardiopulmonary bypass (without aortic crossclamping)
is used.Postoperative Management and Outcomes
Evaluation
Patients were treated postoperatively with medical therapy as with
conventional CABG via sternotomy, including aspirin, beta-blockers, and
anti-cholesterol agents. Patients undergoing MICS CABG with a radial
artery graft were prescribed a dihydropyridine calcium channel blocker
for 6 months. Patients were followed from enrollment to a minimum of 6
months after discharge from the hospital, and all related adverse
events were captured and compiled. Because of the lack of evidence
regarding its effects on graft patency,11-13 clopidogrel use was left to
preferred practice. As such, patients undergoing operation without
cardiopulmonary bypass assistance in Ottawa received clopidogrel for 6
months postoperatively, whereas patients operated with pump assistance
in Ottawa and all patients at Staten Island did not receive clopidogrel
postoperatively.
The primary outcome of the study, graft patency at 6 months, was
evaluated by using CTA. Before image acquisition, metoprolol or diltiazem
(oral or intravenous) was administered if needed, targeting a heart rate of 65
beats/min or less. Patients also received nitroglycerin 0.6 to 0.8 mg
sublingually. An intravenous bi-phasic timing bolus protocol (Staten Island
University Hospital: 100 mL of ioversol injection 74%; OptiRay 350,
Maqllinckrodt Inc, Hazelwood,Mont. University of Ottawa Heart Institute:
15 to 25 mL of iohexal; Omnipaque GE Healthcare, Princeton, NJ, with 40
mL of saline solution) was used to measure transit time. Subsequently,
a tri-phasic protocol (100% contrast, 40%/60% contrast/saline solution
[50 mL], and saline solution [40 mL]) was used to acquire final images.
The volume and rate of contrast were adjusted according to the patient’s
body habitus and scan time. Prospective electrocardiogram-gated images
were acquired during an inspiratory breath-hold with a Lightspeed VCT
(GE Healthcare, Milwaukee, Wis) (64 3 0.625 mm slice collimation,
350 ms gantry rotation, 400-800 mA, 120 kVp). Padding duration when
used was 100 to 150 ms, and all studies were centered at 75%R-R interval.
Images were reconstructed using a slice thickness of 0.625 mm with an
increment of 0.4 mm. Images were reviewed by an experienced coronary
CTA radiologist on a workstation (AW 4.1 Advantage, GE Healthcare).
In an effort to reduce radiation exposure, scan parameters such as max
on mA, kVp, and z-axis coverage were monitored and adjusted by the
CTA radiologist.
Interpretations were performed with axial data sets, maximum inten-
sity projections, or curved multiplanar reconstructions (Figure 1) at the
discretion of the radiologist. The degree of graft stenosis was graded
and classified according to the Fitzgibbon score, as follows:ery c January 2014
FIGURE 1. Computed tomography reconstruction of grafts performed with MICS CABG. A graft course similar to that seen with conventional CABG is
observed. A, Curved multiplanar reconstructed image shows a patent SVG to the posterior descending artery. B, Curved multiplanar reconstructed image
demonstrates an SVG to the first obtuse marginal of the left circumflex system. C, Curved multiplanar image of the LITA-LAD. LAD, Left anterior
descending; LITA, left internal thoracic artery; OM1, obtuse marginal 1; PDA, posterior descending artery; SVG, saphenous vein graft.
TABLE 1. Preoperative patient characteristics (N ¼ 91)
Gender, n (%)
Female 10 (11%)
Male 81 (89%)
Age, mean  SD (y) 64.1  8.3
Race, Caucasian, n (%) 81 (89%)
Smoking status, n (%)
Current 16 (18%)
Previous 43 (47%)
Never 32 (35%)
Family history of premature CAD 55 (60%)
Medical history
LVEF, mean  SD (%) 51.3  10.8
Percutaneous coronary intervention 16 (18%)
Myocardial infarction 28 (31%)
Cerebrovascular accident 2 (2%)
Diabetes mellitus requiring treatment 27 (30%)
Hyperlipidemia requiring treatment 81 (89%)
Renal insufficiency 1 (1%)
CAD, Coronary artery disease; LVEF, left ventricular ejection fraction; SD, standard
deviation.
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DA ¼ excellent graft with unimpaired runoff, B ¼ stenosis reducing
caliber or distal anastomosis to less than 50% of the graft, and
O ¼ occlusion.14-16
Statistical Analyses
Results are reported according to the intent-to-treat principle,with patient
characteristics described from the time of enrollment and surgical and post-
operative outcomes analyzed from beginning of the operation. Continuous
data are expressed as means  standard deviation, and discrete data are
expressed as numbers (percentage). Generalized estimating equations anal-
ysis was performed to assess the association of potential clinical predictors
with graft Fitzgibbon score at 6 months. Single predictor and multiple pre-
dictor models included age, gender, graft conduit (SVG vs LITA), target
location (right coronary vs LAD vs circumflex), left ventricular ejection
fraction, use of cardiopulmonary bypass, and blood transfusion requirement.
For the generalized estimating equations, a Fitzgibbon score of A or B was
considered a success and O was considered a failure. Analyses were per-
formed in SAS version 9.2 (SAS Institute, Inc, Cary, NC).
RESULTS
Between 2010 and 2012, we enrolled 91 patients with
CAD who were referred for CABG and scheduled to
undergo MICS CABG at Staten Island University Hospital
or University of Ottawa Heart Institute. All operations were
performed by J. T. M. at Staten Island University Hospital
(N¼ 46) or by M. R. at University of Ottawa Heart Institute
(N ¼ 45).The Journal of Thoracic and CaThe preoperative characteristics of the patients are shown
in Table 1. The patients ranged in age from 44 to 79 years
(mean, 64.1 years), and 81 were male. Mean height wasrdiovascular Surgery c Volume 147, Number 1 205
TABLE 2. Perioperative results (N ¼ 89)
No. of conduits
1 21 (24%)
2 21 (24%)
3 43 (48%)
>4 4 (4.5%)
No. of distal anastomoses, median 3.0
No. of distal anastomoses, mean  SD 2.3  0.9
Use of cardiopulmonary bypass
Pump assistance without aortic crossclamping 21 (24%)
Off-pump 68 (76%)
Conversion to sternotomy 0
Incomplete revascularization 0
Blood transfusion intraoperatively 5 (5.6%)
Ventilation time (intubation to extubation, min), mean SD 538  255
Reopening 2 (2.2%)
Blood transfusion postoperatively 20 (23%)
Aortic complication, MI, CVA, or death 0
Data are n (%), unless otherwise stated. CVA, Cerebrovascular accident;MI,myocar-
dial infarction; SD, standard deviation.
TABLE 3. Adverse events and outcomes at 6 months follow-up
Occurrence of study adverse events over 6-mo course of
study (N ¼ 89)
Peripheral vascular complication 0
Pleural effusion 14 (15%)
Atrial fibrillation 15 (17%)
Renal insufficiency 1 (1.1%)
Vein harvest site infection 1 (1.5%)
Superficial chest wound infection 2 (2.2%)
Deep chest wound infection 0
Primary outcome at 6 mo
No. of patients/grafts assessed by CTA 72/165
Fitzgibbon grade A 150 (91%)
Fitzgibbon grade B* 1 (0.6%)
Fitzgibbon grade O 14 (8.5%)
Patent LITA grafts 72 (100%)
Patent SVGs 76 (85%)
Overall graft patencyy 151 (92%)
Data are n (%), unless otherwise stated. CTA, Computed tomography angiography;
LITA, left internal thoracic artery; SVG, saphenous vein graft. *In an SVG. yThree
of 4 radial grafts used in the study demonstrated Fitzgibbon grade A patency. One
radial graft was occluded (grade O).
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D173  8 cm (range, 150-189 cm), and mean weight was 86
 15 kg (range, 57-138 kg). Eighty-four patients (92%) and
37 patients (41%) were taking aspirin and clopidogrel,
respectively, before the operation. Symptomatic multivessel
CAD, present in 68 patients (75%), was the most common
indication for surgery.Perioperative Results
Twopatients urgently underwent operation by sternotomy
before their scheduled MICS CABG. Of the 89 patients
brought to the operating room with the intent to perform
MICS CABG, all received the operation without conversion
to sternotomy. Table 2 displays the perioperative results. The
mean number of grafts was 2.3 0.9, and 47 patients (53%)
received 3 or more grafts. Cardiopulmonary bypass assis-
tance was used in 21 patients (24%), with a mean duration
of 96  49 minutes. A blood product transfusion was
required in 24 patients (26%). Complete revascularization,
that is, of each major myocardial territory subtended by a
coronary artery of 1.5 mm or more in diameter with stenosis
70% or greater, was achieved in all patients.
Two patients (2.2%) returned to the operating room for
bleeding, and 15 patients (17%) had atrial fibrillation.
Clopidogrel use had no statistically significant impact on
return to the operating room or on blood loss. The median
hospital length of stay was 4 days (range, 3-9 days).
A left pleural effusion developed in 14 patients (15%),
none of whom required drainage, and there were no other
major adverse events.Postoperative Results
Follow-up to 6 months was 100% complete. None of
the patients experienced an aortic complication, repeat206 The Journal of Thoracic and Cardiovascular Surgrevascularization, myocardial infarction, cerebrovascular
accident, or death. Eighty-two patients (92%) were free
from any degree of angina; 5 patients (6%) had Canadian
Cardiovascular Society (CCS) class I angina, and 2 patients
(2%) had CCS class II angina. A total of 5 patients (6%)
had chest pain that could possibly be related to the thoracot-
omy, including the 2 patients (2%) considered to experi-
ence CCS class II angina. Although it seems likely that
the cause of the pain in these 2 patients was angina or
post-thoracotomy pain, these patients are counted twice
(ie, as having both CCS class II and post-thoracotomy
pain) because the cause of the chest pain was unclear.
Graft Patency of Minimally Invasive Coronary
Artery Bypass Grafting at 6 Months Postoperatively
The primary outcome of the study (ie, graft patency 6
months after MICS CABG) is described in Table 3. Overall
graft patency was 151 of 165 grafts (92%) and was 100%
for the LITA and 85% for SVG (P< .001, Fisher exact).
A generalized estimating equations model examining the
association between graft occlusion and age, gender, left
ventricular grade, use of cardiopulmonary bypass, use of
clopidogrel, or a requirement for transfusion did not reveal
any statistically significant predictor (coefficients not shown).
Curved multiplanar reconstruction images of typical
graft configurations to the posterior descending artery
(Figure 1, A) and the first obtuse marginal of the circumflex
artery (Figure 1, B) are shown. A typical LITA-LAD
reconstruction is shown in Figure 1, C.
DISCUSSION
This prospective study is the first to systematically
evaluate and report the patency outcomes of the MICSery c January 2014
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DCABG operation. Over the years, a sizable number of these
minimally invasive, multivessel CABG operations have
been taught, adopted, and performed in the United States,
Canada, Italy, India, Japan, and other countries. Conse-
quently, it is important for surgeons who want to perform
or appraise this technique to be provided with validated,
objective quantification of the efficacy and quality of this
procedure. Whether MICS CABG in its current form is
applicable to all centers, all surgeons, and all patients
remains open to debate, but the key, novel finding of this
study is that multivessel coronary revascularization can be
performed minimally invasively in a large number of
patients with excellent procedural and patency outcomes.
One of the findings in this study was that although overall
patency was high at 92%, it was significantly higher for
LITA grafts than for SVGs. This has often been noted before
and leads to the hypothesis that a hybrid approach
combining minimally invasive bypass of the LAD with
the LITA constitutes one area where the MICS CABG
operation may find its greatest technical approachability,
best patency results, and potentially highest institutional
applicability, at least during the initial learning curve phase.
The availability of MICS CABG may stimulate increased
referrals for single-vessel LAD disease, whether approach-
able by percutaneous coronary intervention or not,6,17
because after the results of the FREEDOM trial,
controversy may exist with regard to the management of
proximal LAD disease in diabetic patients.3 In this regard,
it is important to note that MICS CABG consisting of
single-vessel LITA-LAD is different than the older mini-
mally invasive direct coronary artery bypass (MIDCAB)
operation. In this regard, the principles and outcomes of
various minimally invasive cardiac procedures were
recently reviewed by our group.18 With MICS CABG, the
incision is more lateral (starting at the mid-clavicular
line) than with MIDCAB, the LITA is harvested over its
entire cephalad length (up to the subclavian vein) because
of the more lateral approach and better exposure,9 and the
LAD is seen over its entire anterior course, therefore allevi-
ating issues of suboptimal target site selection and error
with vessel identification that have been experienced with
MIDCAB. Such procedural attributes of MICS CABG
may be reflected by the perfect patency observed on the
LITA-LAD axis in this study, which to our knowledge has
not been reported in a MICS CABG series of this size.
This represents a testament to the quality of the MICS
CABG operation, making a logical contender to consti-
tuting the minimally invasive surgical component of any
hybrid revascularization approach.19
Last year, the Sternotomy versus Thoracotomy (STET)
trial revealed no overall clinical benefit of anterolateral
left thoracotomy over median sternotomy on morbidity
and health care resource use in patients undergoing
off-pump CABG; however, that study did not address theThe Journal of Thoracic and Caadvantages inherent to MICS CABG, namely, reduced
transfusion, reduced infection, and reduced time to return
to full physical activity.10 Our 2 centers have performed
MICS CABG in more than 1000 patients with excellent
clinical outcomes up to 6 years,7 and the present study
confirms a mechanistic basis for the favorable outcomes
previously observed,6 with patency results on par with
that of conventional CABG.20Study Limitations
This study was performed in 2 centers with expertise and
a relatively high adoption rate in MICS CABG,6 which may
have led to patient selection and a potential for outcome
nongeneralizability, including better results than might
otherwise have been observed. The graft patency assess-
ment was performed by using CTA alone, without
correlation with invasive angiography. Although less
invasive than coronary angiography and sensitive for graft
occlusion, the accuracy of coronary CTA for assessing graft
stenosis has been shown to be somewhat lower and
assessing the adequacy of the distal anastomosis to be
problematic if it is of small size.15 In addition, assessment
of native vessels distal to the anastomosis may prove
challenging, and artifacts resulting from the presence of
surgical clips along arterial grafts may cause difficulty in
image interpretation. Only 81% of patients returned for
CTA; however, this proportion is equivalent to that of other
important studies in the field, which reported a follow-up
rate of 76% to 81% for invasive angiography during the
first year.11,20,21 Finally, the study reports on relatively
short-term major adverse events, and longer-term follow-
up will be necessary to truly ascertain the long-term
effectiveness of the MICS CABG operation.CONCLUSIONS
Despite the aforementioned shortcomings, the present
prospective study constitutes the first to systematically
evaluate and report the patency outcomes of multivessel
MICS CABG, thereby providing the first true objective
measure of the subclinical efficacy of this operation.
Although clinical and angiographic results were on par
with conventional CABG, further research with regard to
the wide applicability of MICS CABG and its comparison
with percutaneous interventions and conventional CABG
remains to be undertaken.
Our cardiac surgery departments thank the research team
members (Jessica Cierzan, Kristin Lawman, and Hang Nguyen)
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upholding the highest standards in patient care; and Sarika Naidoo
(Ottawa) and Athena DeCarlo (Verrazano Radiology, Staten
Island, NY) for patient follow-ups.rdiovascular Surgery c Volume 147, Number 1 207
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Dr Valavanur Subramanian (New York, NY). Marc, congratu-
lations. Finally you are showing some patency data in the mix.
Here is the problem I have. We are now talking about what is
the best second arterial graft, because 2 arterial grafts are
important for long-term survival. It is a very low-risk group of
patients. Now you are advocating minimally invasive multivessel
grafting as a standard SVG as a LITA graft. How do you defend
your position going forward for the sake of just continuing the
SVG in this group of patients?
Dr Ruel. I didn’t hear all of your question, but I think you are
asking about the second and third arterial grafts. I agree with
you; however, there are 3 problems with CABG. First, we have
to make it a 0%mortality operation, and we are close to that, either
minimally invasively or open.
Second, we have to try to reach for 100% patency. We led the
Clopidogrel After Surgery for Coronary Artery Disease
(CASCADE) Trial before, and I would like to show some
discussion slides. Obviously with CASCADE, the 1-year
angiographic patency was extremely high. In CASCADE, even
the SVG patency in the hands of the Principal Investigators, Pierre
Voisine and I, was 96% at 1 year on angiograms. So this was
extremely high. We need to try to reach that confluence where
we have a perfect operation with zero risk.
There is a third problem with CABG, and it is its invasiveness,
which we also have to work on. What we have shown today is
not that MICS CABG is the perfect durable operation. I don’t think
we have the same results here as when doing LITA, right internal
thoracic artery, or radial on everyone, but we certainly have made
great strides with regard to decreasing the invasiveness of CABG.
The next step may be to take a right internal thoracic artery
down with a robot and give everyone bilateral thoracic arteries.
Now that we have shown that the patency of doing a proximal
on the aorta through a small incision is high, it is a leap forward
toward achieving that goal.
Dr Subramanian.We ought to be honest in comparing patency
with a gold standard, angiography, because validation with
computed tomography, as you have shown, Fitzgibbon score,
and anastomotic quality is not there. So I wish Medtronic had
supported you to do a good angiography study with the money
involved, and it’s important for us to do it.
Dr Ruel. Angiographic quality, first, is something you
can look at with computed tomography. It’s not always
perfect visualization, especially if the heart rate is more than
65 beats/min, but there can be good definition of the anastomosis
there. You also have to look at clinical outcomes; there was not a
single patient who needed revascularization, so a subradiologic
signal, if you will, is unlikely.
I too believe that when you add everything together, computed
tomography is not perfect. It actually will make some grafts not
easy to evaluate, especially if there are a lot of clips or lots of
motion. But angiography is not perfect either and can miss grafts.
Again, it is important that we do those patency trials. There is no
perfect way to assess patency, but it’s important to carry on and do
those, in my opinion.
Dr Nikolaos Bonaros (Innsbruck, Austria). The main charac-
teristic of your series is that you construct the proximalery c January 2014
Ruel et al Acquired Cardiovascular Diseaseanastomosis in the aorta and you do not do a Y or T graft. Can
you give us some insight as to how you make your decision if
you are doing a sequential anastomosis or an anastomosis to the
aorta?
Dr Ruel.We described our techniques in other articles, and it is
beyond the scope of today’s talk, but you are absolutely right.
What we generally do is 1 vein graft equals 1 proximal anasto-
mosis, and relatively few sequentials. The configuration one sees
on a computed tomography scan essentially is exactly the same
as the configuration would be after an open multivessel CABG.
There may be a way to maximize the use of sequential grafts
with this operation, but you can easily do up to 3 proximal
anastomoses on the ascending aorta with this technique.
The other defining feature is not just the proximals. In this
series, as you have seen, a lot of posterior descending arteriesThe Journal of Thoracic and Cawere grafted, obtuse marginals 3 and 2, and this is another level
of minimally invasive applicability that wasn’t seen before.
Dr Vivek Rao (Toronto, Canada). Marc, can you just clarify,
when you do pump assistance, is it femoral cannulation?
Dr Ruel. It is, yes.
Dr Rao. Any femoral complications from that?
Dr Ruel.No, there were not. Actually in the overall experience,
there are now more than 1000 patients in the series by Joe and me,
and we haven’t had serious peripheral vascular complications from
this operation.
These are obviously somewhat selected patients. If I see some-
one in whom I’m going to do 4 grafts, one of the first things I do in
clinic is to make sure that the femoral pulses are nice and bound-
ing, and that we are not going to perform a challenging multivessel
MICS CABG in someone who has a 3-mm external iliac vessel.rdiovascular Surgery c Volume 147, Number 1 209
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